Liquidia Corporation LQDA
LQDA Rating
LQDA Rating Factors
LQDA Company Overview
Liquidia Corporation is a U.S.-based biopharmaceutical company focused on the development, manufacturing, and commercialization of therapies for rare cardiopulmonary diseases. The company operates primarily within the biotechnology and specialty pharmaceutical industries, with a strategic emphasis on pulmonary arterial hypertension (PAH) and related pulmonary conditions. Liquidia’s core business centers on leveraging its proprietary PRINT technology platform, a particle engineering and drug delivery technology designed to produce precisely engineered particles for inhaled therapeutics and other pharmaceutical applications.
The company’s primary revenue drivers are product commercialization activities, licensing arrangements, and development-stage therapeutic programs. Liquidia is best known for YUTREPIA, an inhaled dry-powder formulation of treprostinil intended for the treatment of PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD), subject to ongoing regulatory and legal developments. Liquidia evolved through a combination of technology platform development and strategic acquisitions, including the acquisition of RareGen, LLC, which expanded its commercial infrastructure and rights related to pulmonary hypertension therapies. The company positions itself competitively through its proprietary drug delivery capabilities, focus on orphan diseases, and specialization in inhaled therapies targeting underserved patient populations.
LQDA Income Statement
LQDA Balance Sheet
LQDA Price History
LQDA Valuation
LQDA Dividends and Shares
LQDA Corporate Info
Suite 100
Morrisville, NC 27560